BRAF mutations can control processes such as invasion and metastasis, since BRAF down‐modulation reduces MAPK and MMP‐2 activities, and the invasive ability in a melanoma model.38 In particular, after the acquisition of vemurafenib resistance, melanoma cells showed reactivation of the MAPK pathway, including MEK and ERK proteins, and a pronounced CRAF phosphorylation.32, 38, 39, 40, 41 Our data also indicate that melanoma cells expressing VEGFR‐1 are more invasive than VEGFR‐1 deficient cells. The gene discussed is MAP2K7; the disease is melanoma.